Jubilant Biosys Limited
Venugopala Reddy Pagadala is an accomplished financial professional currently serving as the Chief Financial Officer at Jubilant Biosys Limited since July 2025. Previously, Venugopala held significant roles at Dr. Reddy's Laboratories as Cluster Finance Head for CTOs, overseeing finance for eight manufacturing plants globally and contributing to over $1 billion in sales. At Syngene International Limited, Venugopala managed P&L responsibilities for businesses worth over $250 million, focusing on sustainable growth and strategic partnerships. Earlier experience includes leadership positions at Cipla, where Venugopala drove operational efficiency and financial strategies, and at Nestle India Limited and Bharat Petroleum Corporation Limited. Venugopala's educational background includes qualifications as a Chartered Accountant, Associate of Company Secretaries, and ICWA, underscoring a strong foundation in accounting and finance.
This person is not in any teams
This person is not in any offices
Jubilant Biosys Limited
1 followers
Jubilant Biosys Ltd (JBL) offers end-to-end CRDMO solutions in Structural Biology, Computational Chemistry, Medicinal & Synthetic Chemistry, in-vitro and in-vivo Biology, DMPK, Toxicology, Process R&D & Manufacturing to various Biotech & Pharma companies pursuing drug discovery, development and manufacturing. Jubilant Biosys Limited (JBL) is a subsidiary of Jubilant Pharmova, serving the global life sciences, agrochemicals and specialty chemicals industry through its research centers & manufacturing facilities in India. Jubilant’s services in discovery research include; Jubilant’s services in discovery research includes; • Target Identification/Target Validation to Lead Optimization/ Preclinical candidate, for multiple therapeutic areas viz; Oncology, Metabolic Disorders, CNS, Pain and Inflammation. • Functional services comprising of computational chemistry/ molecular modeling, medicinal chemistry, synthetic chemistry, scale-up (Non-GMP & GMP), structural biology, ADME-PK,in-vitro and in-vivo biology and IND enabling GLP toxicology.